去勢抵抗性前立腺癌に対するドセタキセル療法の治療効果・投与継続期間に関する検討
書誌事項
- タイトル別名
-
- Clinical Study on the Efficacy and Continuous Docetaxel Based Chemotherapy Treatment for Castration-Resistant Prostate Cancer
- キョセイ テイコウセイ ゼンリツセンガン ニ タイスル ドセタキセル リョウホウ ノ チリョウ コウカ ・ トウヨ ケイゾク キカン ニ カンスル ケントウ
この論文をさがす
説明
We report a retrospective study on the efficacy, adverse events and the factors for continuous docetaxel (DOC) therapy for patients with castration-resistant prostate cancer (CRPC). Between April 2007 and April 2015, 37 CRPC patients were treated with DOC therapy at Kanazawa Medical University Hospital. DOC was administered every 3 weeks at 70 mg/m2. Prostatic specific antigen (PSA) level, adverse events, cycles of DOC therapy, survival time and clinical passage were examined. Fifteen patients showed a decrease in PSA level of 50% or more, 9 patients showed less than 50% decrease in PSA level and 13 patients showed no decrease in PSA level. Adverse effect of grade 3 consisted of neutropenia in 29.7% and leukocytopenia in 10.8%. The median number of treatment cycles was 11.7 courses. The patients were divided into two groups ; the first group comprised of 26 patients who received short-term DOC therapy (≤10 cycles) and the second group comprised of 11 patients who received long-term DOC therapy (≥11 cycles). The 1-year survival rate was 59 and 100% for the short-term and long-term groups, respectively. Long-term treatment was related to pretreatment PSA nadir, time to progression of CRPC and serum lactate dehydrogenase level.
収録刊行物
-
- 泌尿器科紀要
-
泌尿器科紀要 63 (9), 351-357, 2017-09-30
泌尿器科紀要刊行会
- Tweet
詳細情報 詳細情報について
-
- CRID
- 1390290699821034112
-
- NII論文ID
- 120006353840
-
- NII書誌ID
- AN00208315
-
- HANDLE
- 2433/227505
-
- NDL書誌ID
- 028534684
-
- ISSN
- 00181994
-
- PubMed
- 28992664
-
- 本文言語コード
- ja
-
- 資料種別
- departmental bulletin paper
-
- データソース種別
-
- JaLC
- IRDB
- NDLサーチ
- PubMed
- CiNii Articles
- OpenAIRE
-
- 抄録ライセンスフラグ
- 使用可